FDA re­jects first nasal spray al­ter­na­tive to EpiPen for those with se­vere al­ler­gies

ARS Phar­ma­ceu­ti­cals re­vealed late Tues­day evening that the FDA re­ject­ed what would have been the first ep­i­neph­rine nasal spray.

The FDA re­quest­ed an­oth­er phar­ma­co­ki­net­ic/phar­ma­co­dy­nam­ic study …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.